Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Renal Safety of Entecavir vs Tenofovir Alafenamide in HBV-ACLF
NCT05453448Completed
- Sponsor
- Xiangya Hospital, Central South University
- Start
- May 2022
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of tenofovir alafenamide in hepatitis B (HBV) and acute-on-chronic liver failure (ACLF) (2 arms), sponsored by Xiangya Hospital, Central South University. Primary endpoint: Survival rates without transplantation at 48 weeks. Started May 2022; status: completed.
02
Drugs
tenofovir alafenamide
03
Conditions
hepatitis B (HBV)acute-on-chronic liver failure (ACLF)
Beyond the preview
Go deeper on NCT05453448.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05453448.